Document Detail

Methylxanthines in asthma.
MedLine Citation:
PMID:  20859807     Owner:  NLM     Status:  MEDLINE    
Methylxanthines represent a unique class of drugs for the treatment of asthma. The methylxanthine theophylline has demonstrated efficacy in attenuating the three cardinal features of asthma - reversible airflow obstruction, airway hyperresponsiveness, and airway inflammation. At doses achieving relatively high serum levels in which toxic side effects are sometimes observed, direct bronchodilatory effects of theophylline are recognized. At lower serum concentrations, theophylline is a weak bronchodilator but retains its capacity as an immunomodulator, anti-inflammatory, and bronchoprotective drug. Intense investigation into the molecular mechanisms of action of theophylline has identified several different points of action. Phosphodiesterase inhibition and adenosine receptor antagonism have both been implicated in promoting airway smooth muscle relaxation and bronchodilation. Similar mechanisms of action may explain the inhibitory effects of theophylline on immune cells. At lower concentrations that fail to inhibit phosphodiesterase, effects on histone deacetylase activity are believed to contribute to the immunomodulatory actions of theophylline. Since anti-inflammatory and immunomodulatory effects of methylxanthines are realized at lower serum concentrations than are required for bronchodilation, theophylline's predominant role in asthma treatment is as a controller medication for chronic, persistent disease.
Stephen L Tilley
Related Documents :
7971387 - Use of bronchodilators: implications for nurses.
3480417 - Emergency outpatient treatment of asthma.
2029157 - Rational drug strategy in bronchial asthma.
3826597 - Postoperative headache in young patients after spinal anaesthesia.
10129157 - The way to economic prescribing.
23312867 - Evaluation of praziquantel effects on echinostoma paraensei ultrastructure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Handbook of experimental pharmacology     Volume:  -     ISSN:  0171-2004     ISO Abbreviation:  Handb Exp Pharmacol     Publication Date:  2011  
Date Detail:
Created Date:  2010-09-22     Completed Date:  2011-01-03     Revised Date:  2011-04-12    
Medline Journal Info:
Nlm Unique ID:  7902231     Medline TA:  Handb Exp Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  439-56     Citation Subset:  IM    
Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Asthma / drug therapy*
Lung / drug effects
Phosphodiesterase Inhibitors / pharmacology
Purinergic P1 Receptor Antagonists / pharmacology
Theophylline / pharmacology,  therapeutic use*
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Purinergic P1 Receptor Antagonists; 58-55-9/Theophylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The cardiovascular effects of methylxanthines.
Next Document:  Methylxanthines and inflammatory cells.